American Tower(AMT)

Search documents
American Tower: Buy The Drop While The Market Is Fearful
Seeking Alpha· 2024-12-19 15:00
iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios.It pays to be patient, especially when it comes to income stocks. That’s because being able to layer in at lower prices translates into a higher dividend yie ...
5 Magnificent Dividend Growth Stocks Down 24% to 41% to Buy Before 2025 for a Lifetime of Passive Income
The Motley Fool· 2024-12-19 09:45
If you're an investor looking to grow your long-term passive income prospects, the five stocks in this article could be perfect to add to your portfolio before 2025.Whether you prefer high-yield dividend payers like American Tower (AMT -4.35%), The Hershey Company (HSY -2.91%), and Public Storage (PSA -4.30%) or quickly growing payouts like those from MTY Food Group (MTYF.F -2.59%) or Zoetis (ZTS -2.21%), these businesses offer the potential for a lifetime of passive income.Currently down between 24% and 41 ...
All I Want For Christmas Are A Few Great REITs
Seeking Alpha· 2024-12-16 12:00
Brad, along with HOYA Capital, lead the investing group iREIT®+HOYA Capital. The service covers REITs, BDCs, MLPs, Preferreds, and other income-oriented alternatives. The team of analysts has a combined 100+ years of experience and includes a former hedge fund manager, due diligence officer, portfolio manager, PhD, military veteran, and advisor to a former U.S. President.Brad Thomas has over 30 years of real estate investing experience and has acquired, developed, or brokered over $1B in commercial real est ...
American Tower Stock Falls 16% in 3 Months: Time to Buy, Sell or Hold?
ZACKS· 2024-12-12 17:41
Shares of American Tower (AMT) have experienced a more than 16% decline in the past three months, closing at $199.59 on Wednesday on the NYSE. In the past three months, the stock has underperformed the Zacks REIT and Equity Trust - Other industry and the S&P 500 composite.This prominent independent owner, operator and developer of multitenant communications real estate has faced a few challenges this year, hindering its growth trajectory. Its sale of the troubled Indian tower operations to Data Infrastructu ...
American Tower Corporation (AMT) UBS Global Media & Communications Conference (Transcript)
2024-12-10 20:35
American Tower Corporation (NYSE:AMT) UBS Global Media & Communications Conference December 10, 2024 12:45 PM ET Company Participants Rod Smith - EVP and CFO Conference Call Participants Batya Levi - UBS Batya Levi Great. Thanks, everyone, joining our next session with American Tower. Excited to have Rod Smith, EVP and CFO with us. And I'm Batya Levi with the communications team at UBS. Rod, thank you so much for joining us. Rod Smith You're welcome. Thanks for having me. It's great to be here. Batya Levi G ...
2 Magnificent S&P 500 Dividend Stocks to Buy for a Lifetime of Passive Income
The Motley Fool· 2024-12-01 11:30
Finding stocks that have long-lasting megatrends working in their favor can be an excellent way to generate new investment ideas. This notion is especially true when the businesses are market share leaders in their niche.Two companies that meet these requirements are American Tower (AMT -0.14%) and Public Storage (PSA -0.94%). If people are using data or need room to store things, these two stocks will likely benefit. With total returns of 760% and 3,590% since 2000 compared to the S&P 500's mark of 540%, t ...
The U.S. Election's Impact On REITs
Seeking Alpha· 2024-11-30 13:15
The decisive electoral victory of Donald Trump and the Republican Party sent an immediate shock wave through the stock market, as investors quickly priced in the new reality awaiting us in 2025 and beyond.If you want full access to our Portfolio and all our current Top Picks, feel free to join us at High Yield Landlord for a 2-week free trial.We are the largest and best-rated real estate investor community on Seeking Alpha with 2,000+ members on board and a 4.9 /5 rating from 500+ reviews:You won't be charg ...
Should You Retain American Tower Stock in Your Portfolio Now?
ZACKS· 2024-11-25 19:00
American Tower (AMT) boasts an extensive, geographically diversified communication real estate portfolio. The company will likely benefit from increased investment by wireless carriers in 4G and 5G networks. Solid business fundamentals and a prudent capital-allocation strategy augur well for growth.However, high customer concentration and the ongoing consolidation in the wireless industry are likely to weigh on its top-line growth.What’s Aiding AMT?The advancement in mobile technology, such as 4G and 5G, an ...
3 REITs With High Dividend Growth Prospects In 2025
Seeking Alpha· 2024-11-21 13:15
Maybe “hate” is too strong a word, but we certainly would never invest our money into them or recommend othersWe love real estate investment trusts (“REITs”), but we hate REIT ETFs ( VNQ ) and mutual funds.If you want full access to our Portfolio and all our current Top Picks, feel free to join us at High Yield Landlord for a 2-week free trial.We are the largest and best-rated real estate investor community on Seeking Alpha with 2,000+ members on board and a 4.9 /5 rating from 500+ reviews:You won't be char ...
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
GlobeNewswire News Room· 2024-11-21 12:05
LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the GenTLE Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (MTLE). “The dosing of the first patient in our Phase I/II trial in temporal lobe epilepsy represents an important milestone for uniQure and ou ...